Pair page
Cerebrolysin with DS5
Mechanism-tag overlap and published literature for Cerebrolysin and DS5, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
neurotrophic-brain-bioregulator
blenddihexa-semax-nootropic-stack
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cerebrolysin and DS5 have published these mechanism-level observations. Not a co-administration recommendation.
Porcine brain peptide hydrolysate with 200+ clinical trials. A higher-evidence-base neurotrophic option for users seeking clinical-grade data. Mechanistically orthogonal to both DS5 components.
Quick facts
Cerebrolysin
DS5
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Cerebrolysin | Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, von Steinbüchel N, Strilciuc S, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(2):… PMID 33620612 | meta-analysis |
| 2018 | Cerebrolysin | Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PMID: 29248999. PMID 29248999 | meta-analysis |
| 2015 | Cerebrolysin | Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905. PMID 25832905 | meta-analysis |
| 2020 | Cerebrolysin | Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PMID: 31494820. PMID 31494820 | human trial |
| 2020 | Cerebrolysin | Woo PYM, Ho JWK, Ko NMW, Li RPT, Jian L, Chu ACH, Kwan MCL, Chan Y, Wong AKS, Wong HT, Chan KY, Kwok JCK. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol.… PMID 33143640 | human trial |
| 2017 | Cerebrolysin | Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 20… PMID 29075343 | human trial |
| 2016 | Cerebrolysin | Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. PMID: 26564102. PMID 26564102 | human trial |
| 2016 | Cerebrolysin | Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. PMID: 26365023. PMID 26365023 | human trial |
| 2012 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PM… PMID 22282884 | human trial |
| 2010 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia — CASTA. Int J Stroke. 2010;5(4):310-313. PMID: 19765131. PMID 19765131 | human trial |
| 2005 | Cerebrolysin | Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005;112(3):415-428. PMID: 15583955. PMID 15583955 | human trial |
| 2023 | Cerebrolysin | Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231. PMID 37052231 | human study |
| 2024 | DS5 | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2018 | DS5 | Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. | human study |
| 2021 | DS5 | Sun X, Deng Y, Liang J, Lin Y, Song J, Zhao S, Zhuang G, Jia Z. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Oct 28;11(11):1421. PMID: 34827487. PMID 34827487 | preclinical, in vivo |
| 2006 | DS5 | Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of adrenocorticotropin (4-10), activates expression of BDNF in rat basal… | preclinical, in vivo |
| 2026 | DS5 | WADA Prohibited List 2026. World Anti-Doping Agency. | regulatory / registry |
| 2025 | DS5 | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
| 2015 | DS5 | Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. PMID: 25674052. PMID 25674052 | research article |
| 2014 | DS5 | Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402. PMID: 25187433. RETRACTED April 2025. PMID 25187433 | research article |
| 2013 | DS5 | McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013 Jan;344(1):141-54. PMID: 23055539. (Foundational… PMID 23055539 | research article |
Related pair pages
More research context
Frequently asked
Have Cerebrolysin and DS5 been studied together?
Researchers have published mechanistic-level co-administration discussion of Cerebrolysin and DS5. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cerebrolysin and DS5 share?
Cerebrolysin and DS5 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cerebrolysin and DS5?
Cerebrolysin: Not approved (US). DS5: Research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cerebrolysin and DS5?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cerebrolysin profile and the DS5 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026